Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit, and to learn more about Covance Drug Development, visit

More Information

Primary IR Contact
Scott Frommer
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Change (%) Stock is Down 2.3 (1.65%)
52 Week Low$136.15
Market Cap$13,864,669,000
Rolling EPS14.06
PE Ratio9.7731
Shares Outstanding100,900,000
Data as of 12/14/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $137.41 with a 52 week high of $190.35 and a 52 week low of $136.15.
Recent News & Events
12/07/18 - 8:45 a.m.
Covance Xcellerate® Wins Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at 14th Annual Scrip Awards
12/06/18 - 5:50 p.m.
Covance Honored with Frost & Sullivan Asia Pacific Award for Fifth Consecutive Year
11/30/18 - 6:56 a.m.
LabCorp Updates Full-Year 2018 Guidance
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 2.3

SellStrong Buy
Unable to fulfill request.
SEC Filings
Filing DateForm
12/07/184 XBRL SEC Filing Unavailable
12/07/188-K XBRL SEC Filing Unavailable
12/07/188-K XBRL SEC Filing Unavailable
11/30/188-K XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
Gary M. HuffChief Executive Officer, LabCorp Diagnostics
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
F. Samuel Eberts IIISenior Vice President, Chief Legal Officer and Secretary
Lisa J. UthgenanntChief Human Resources Officer
Brian J. CaveneyChief Medical Officer
Ownership Summary
 HoldersValue ($MM)% O/SShares
Mutual Fund1,6248,157.5449.750,122,403
Insider *1768.580.4393,249
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,823,66710.785,78509/30/18
BlackRock Institutional Trust Company, N.A.5,644,2295.6116,89809/30/18
Boston Partners4,465,0744.4-1,202,81809/30/18
State Street Global Advisors (US)4,249,7764.2199,29709/30/18
Nordea Funds Oy1,977,0832.0-75,02709/30/18
Amundi Pioneer Asset Management, Inc.1,925,2541.919,39009/30/18
OppenheimerFunds, Inc.1,662,4021.7-38,37409/30/18
JP Morgan Asset Management1,467,9961.5173,87309/30/18
Dimensional Fund Advisors, L.P.1,425,4171.410909/30/18
Iridian Asset Management LLC1,307,3371.3-451,57109/30/18